A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Panobinostat (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PANORAMA4
- Sponsors Novartis; Novartis Pharmaceuticals
- 21 Feb 2018 Status changed from recruiting to discontinued.
- 07 Oct 2016 Planned End Date changed from 1 Jun 2021 to 1 Feb 2021.
- 07 Oct 2016 Planned primary completion date changed from 1 Jun 2021 to 1 Feb 2021.